Picture ConsulTech GmbH GDPR-compliant E-Col Home Office 650x80px
Document › Details

Arsanis, Inc.. (3/20/18). "Press Release: Arsanis to Present at the Needham & Company 17th Annual Healthcare Conference". Waltham, MA & Vienna.

Region Region New York, NY
  Country United States (USA)
Organisations Organisation Arsanis Inc. (Nasdaq: ASNS)
  Group Arsanis (Group)
  Organisation 2 Needham & Company, LLC
  Group Needham (Group)
Products Product Needham & Company 17th Annual Healthcare Conference 2018 New York
  Product 2 ASN100 (Arsanis)
Index term Index term Arsanis–Needham: investor conference, 201803 supply service Arsanis presents at Annual Needham Healthcare Conference in NY
Persons Person Russo, René (Arsanis 201702 CEO)
  Person 2 Gibbs, Krystle (Ten Bridge Communications 201703)

Arsanis, Inc. (NASDAQ: ASNS), a clinical-stage biopharmaceutical company focused on applying monoclonal antibody immunotherapies to address serious infectious diseases, announced today that CEO René Russo, PharmD, BCPS, will present a company overview at the Needham & Company 17th Annual Healthcare Conference on March 27, 2018, at 12:45 p.m. ET.

A webcast of the presentation will be available on the Arsanis website under “Events and Presentations” or can be accessed at The webcast will be archived for 30 days following the live presentation.

About Arsanis

Arsanis, Inc. is a clinical-stage biopharmaceutical company focused on applying monoclonal antibody (mAb) immunotherapies to address serious infectious diseases. A deep understanding of the pathogenesis of infection, paired with access to some of the most advanced mAb discovery techniques and platforms available today, has positioned Arsanis to build and advance a pipeline of novel mAbs with multiple mechanisms of action and high potency against their intended targets. The company’s lead clinical program, ASN100, is aimed at serious Staphylococcus aureus infections and is being evaluated in a Phase 2 clinical trial for the prevention of S. aureus pneumonia in high-risk, mechanically ventilated patients. In addition to ASN100, the Arsanis preclinical pipeline is comprised of mAbs targeting multiple serious bacterial and viral pathogens, including respiratory syncytial virus.

Arsanis is a U.S. company headquartered in Waltham, Massachusetts, with European research and preclinical development operations headquartered in Vienna, Austria (Arsanis Biosciences GmbH).

For more information, please visit the Arsanis website at

View source version on

Source: Arsanis, Inc.

Media Contact:
Ten Bridge Communications
Krystle Gibbs, 508-479-6358


Investor Contact:
Michael Gray, 781-819-5201
Chief Operating and Chief Financial Officer

Record changed: 2018-03-23


Picture [iito] – Putting Information into Context 650x65px

More documents for Arsanis (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture ConsulTech GmbH Berlin Grant Application and Coordination 650x80px

» top